Search

Your search keyword '"Kelly, Catherine M."' showing total 282 results
Start Over Author "Kelly, Catherine M."
282 results on '"Kelly, Catherine M."'

1. Spatial predictors of immunotherapy response in triple-negative breast cancer

Author

Wang, Xiao Qian, Danenberg, Esther, Huang, Chiun-Sheng, Egle, Daniel, Callari, Maurizio, Bermejo, Begoña, Dugo, Matteo, Zamagni, Claudio, Thill, Marc, Anton, Anton, Zambelli, Stefania, Russo, Stefania, Ciruelos, Eva Maria, Greil, Richard, Győrffy, Balázs, Semiglazov, Vladimir, Colleoni, Marco, Kelly, Catherine M., Mariani, Gabriella, Del Mastro, Lucia, Biasi, Olivia, Seitz, Robert S., Valagussa, Pinuccia, Viale, Giuseppe, Gianni, Luca, Bianchini, Giampaolo, and Ali, H. Raza

Published
2023
Full Text
View/download PDF

2. Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study

Author

García-Sáenz, José Angel, Marmé, Frederik, Untch, Michael, Bonnefoi, Hervé, Kim, Sung-Bae, Bear, Harry, Mc Carthy, Nicole, Gelmon, Karen, Martin, Miguel, Kelly, Catherine M., Reimer, Toralf, Toi, Masakazu, Law, Ernest, Bhattacharyya, Helen, Gnant, Michael, Makris, Andreas, Seiler, Sabine, Burchardi, Nicole, Nekljudova, Valentina, Loibl, Sibylle, and Rugo, Hope S.

Published
2024
Full Text
View/download PDF

6. Virtual oncology clinics during the COVID-19 pandemic

Author

O’Reilly, David, Carroll, Hailey, Lucas, Mairi, Sui, Jane, Al Sendi, Maha, McMahon, David, Darwish, Waseem, McLaughlin, Ronan, Khan, Mohammed Raza, Sullivan, Hazel O, Chew, Sonya, Dennehy, Colum, Kelly, Catherine M., McCaffrey, John, Greally, Megan, Carney, Desmond, and Higgins, Michaela J.

Published
2021
Full Text
View/download PDF

7. Prognostic value of the 6-gene OncoMasTR test in hormone receptor–positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors

Author

Lynch, Seodhna M., Russell, Niamh M., Barron, Stephen, Wang, Chan-Ju A., Loughman, Tony, Dynoodt, Peter, Fender, Bozena, Lopez-Ruiz, Cesar, O'Grady, Anthony, Sheehan, Katherine M., Fay, Joanna, Amberger-Murphy, Verena, Saha, Anurati, Klinger, Rut, Gonzalez, Claudia A., Al-Attar, Nebras, Rahman, Arman, O'Leary, Desmond, Lanigan, Fiona T., Bracken, Adrian P., Crown, John, Kelly, Catherine M., O'Connor, Darran P., and Gallagher, William M.

Published
2021
Full Text
View/download PDF

8. Pregnancy-associated breast cancer: evaluating maternal and foetal outcomes. A national study

Author

Prior, Lisa, O’Dwyer, Richard, Farooq, Abdul Rehman, Greally, Megan, Ward, Cian, O’Leary, Connor, Aslam, Razia, Darwish, Waseem, Ahmed, Nada, Othman, Elly Che, Watson, Geoffrey, Kelly, Deirdre, Gleeson, Jack, Kiely, Lisa, Hassan, Anees, Walsh, Elaine M., O’Reilly, David, Jones, Alfred, Featherstone, Hannah, Lim, Marvin, Murray, Hazel, Hennessy, Bryan T., Smyth, Lillian M., Leonard, Gregory, Grogan, Liam, Breathnach, Oscar, Calvert, Paula, Horgan, Anne M., Coate, Linda, Jordan, Emmet J., O’Mahony, Deirdre, Gupta, Rajnish, Keane, Maccon M., Westrup, Jennifer, Duffy, Karen, O’Connor, Miriam, Morris, Patrick G., Kennedy, M. John, O’Reilly, Seamus, McCaffrey, John, Kelly, Catherine M., Carney, Desmond, Gullo, Giuseppe, Crown, John, Higgins, Michaela J., Walsh, Paul M., and Walshe, Janice M.

Published
2021
Full Text
View/download PDF

9. Breaking through the Noise: Literacy Teachers in the Face of Accountability, Evaluation, and Reform

Author

Kelly, Catherine M., Miller, Sara E., Graham, Karen Kleppe, Bahlmann Bollinger, Chelsey M., and Sanden, Sherry

Abstract

In an era of increased accountability, it is important to understand how exemplary teachers navigate the demands placed on them by their schools, districts, and states in order to support student learning aligned with their beliefs of effective instruction. To understand these negotiations, the authors examined tensions facing exemplary literacy teachers through a qualitative interview study. Participants were 19 experienced Pre-K through sixth-grade teachers from across the United States. Results of the study indicate that teachers experience discrepancies between their beliefs and state and local mandates, and they discuss a variety of strategies for negotiating these discrepancies. Findings suggest that schools can support effective literacy instruction by cultivating cultures of autonomy for teachers and strengthening teachers' sense of agency.

Published
2019

10. Quality of life in women with early-stage and metastatic hormone receptor-positive, HER2-negative breast cancer receiving endocrine therapy.

Author

O'Reilly, David, Farooq, Abdul Rehman, Selvadurai, Paul Nevins, Sheehan, Laura, Molan, Karen, Krishnanivas, Bindu, Mullen, Valerie, McMahon, David, Hadi, Danial, Ahmed, Ahmed, Jennings, Maeve, Carroll, Hailey, Chew, Sonya, Macanovic, Bojan, Brown, Ciara O'Hanlon, Noonan, Sinéad A, Reilly, Seamus O, Connolly, Roisin M, Cahir, Caitriona, and Kelly, Catherine M

Subjects
CROSS-sectional method, HORMONE receptor positive breast cancer, PREDICTION models, RESEARCH funding, BREAST tumors, SCIENTIFIC observation, MULTIPLE regression analysis, FISHER exact test, MULTIVARIATE analysis, CHI-squared test, DESCRIPTIVE statistics, QUALITY of life, ONCOGENES, ENDOCRINE diseases, HEALTH outcome assessment, DATA analysis software, NONPARAMETRIC statistics
Abstract

Introduction Early discontinuation of endocrine therapy (ET) is higher among patients with early breast cancer (EBC) compared to patients with metastatic hormone receptor-positive (HR+) breast cancer (MBC). In our clinical experience the reasons for this may include a significant burden of ET side effects impacting quality of life (QOL) in patients with EBC. We hypothesized that QOL is lower in patients with HR + EBC compared to patients with HR + MBC on ET. Methods We conducted a cross-sectional observational study to assess QOL utilizing FACT-ES & EORTC QLQ C30 tools among patients with EBC and MBC receiving ET across 5 Irish hospitals. Results A total of 417 patients were enrolled—EBC (79% n  = 331) and MBC 21% (n  = 86). Using the FACT-ES, we found no difference in overall QOL by stage (139.2 vs 141, P  = .33). Patients with HR + MBC had a lower symptom burden from ET compared to HR + EBC (61.4 vs 54, P  < .01). In adjusted multivariate linear regression models, there was no difference in QOL for patients with EBC and MBC receiving ET. Conclusions There was no significant difference in overall QOL for patients with EBC and MBC. However, patients with EBC experienced more endocrine symptoms. In adjusted multivariate linear regression models, the stage did not predict QOL. Our results suggest that endocrine symptoms are significant contributors to impaired QOL for patients with EBC but the role of other determinants of QOL (eg, stage) is less clear. Future work could include the development of stage-specific QOL tools and utilization of electronic patient-reported outcomes (ePROs) to identify and manage emergent toxicities. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Multimodal, Technology-Assisted Intervention for the Management of Menopause after Cancer Improves Cancer-Related Quality of Life—Results from the Menopause after Cancer (Mac) Study

Author

Donohoe, Fionán, primary, O’Meara, Yvonne, additional, Roberts, Aidin, additional, Comerford, Louise, additional, Valcheva, Ivaila, additional, Kearns, Una, additional, Galligan, Marie, additional, Higgins, Michaela J., additional, Henry, Alasdair L., additional, Kelly, Catherine M., additional, Walshe, Janice M., additional, Hickey, Martha, additional, and Brennan, Donal J., additional

Published
2024
Full Text
View/download PDF

12. Real-World Analysis of the Clinical and Economic Impact of the 21-Gene Recurrence Score (RS) in Invasive Lobular Early-Stage Breast Carcinoma in Ireland

Author

McSorley, Lynda M., primary, Tharmabala, Mehala, additional, Al Rahbi, Fathiya, additional, Keane, Fergus, additional, Evoy, Denis, additional, Geraghty, James G., additional, Rothwell, Jane, additional, McCartan, Damian P., additional, Greally, Megan, additional, O’Connor, Miriam, additional, O’Mahony, Deirdre, additional, Keane, Maccon, additional, Kennedy, Michael John, additional, O’Reilly, Seamus, additional, Millen, Steve J., additional, Crown, John P., additional, Kelly, Catherine M., additional, Prichard, Ruth S., additional, Quinn, Cecily M., additional, and Walshe, Janice M., additional

Published
2024
Full Text
View/download PDF

16. The internal exile : contemporary Irish playwriting and theatrical production

Author

Kelly, Catherine M.

Subjects
822
Abstract

In recent years Ireland, North and South, has undergone a period of rapid transition. Social and economic advancements in the South and political developments in the North have brought benefits, but have also created for some a sense of confusion and disorientation. Many have become caught between the residual problems of the past and the impact of the new. In the ongoing process of redefining boundaries and attempting to build a more inclusive society, it is important to be aware of the dislocation which exists among groups and individuals in the current cultural climate. My experience of these changing times has been, broadly speaking, as a female Catholic from a middle-class, nationalist background. It is from this perspective that I have explored a variety of political, religious and gender issues, related to the overriding theme of the internal exile in contemporary Irish theatre. Specific chapters address particular concerns. Chapter one provides a historical and cultural context which seeks to place the theme within the macrocosm of a society undergoing change, in addition to outlining the way in which it is represented in and affected by contemporary Irish drama. Chapter two is entitled 'States of mind and the lyricism of theatrical conventions'. It explores a selection of post-sixties plays and identifies a number of different styles of theatre which are being practised in Ireland at the present time. Chapter three discusses the politics of spirituality in relation to Brian Friel's Dancing at Lughnasa. Chapter four focuses on three plays by Marina Carr and considers the role of women. Chapter five looks at politics and gender in two plays about Oscar Wilde; Saint Oscar by Terry Eagleton and The Secret Fall of Constance Wilde by Thomas Kilroy. Chapter six involves a consideration of the political situation in Northern Ireland in respect of the peace process and post-cease-fire plays by a number of playwrights such as Gary Mitchell, Declan Gorman and Michael Harding.

Published
2001

17. Supplementary Figure 2 from A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer

Author

Krop, Ian, primary, Abramson, Vandana, primary, Colleoni, Marco, primary, Traina, Tiffany, primary, Holmes, Frankie, primary, Garcia-Estevez, Laura, primary, Hart, Lowell, primary, Awada, Ahmad, primary, Zamagni, Claudio, primary, Morris, Patrick G., primary, Schwartzberg, Lee, primary, Chan, Stephen, primary, Gucalp, Ayca, primary, Biganzoli, Laura, primary, Steinberg, Joyce, primary, Sica, Lorenzo, primary, Trudeau, Maureen, primary, Markova, Denka, primary, Tarazi, Jamal, primary, Zhu, Zhou, primary, O'Brien, Thomas, primary, Kelly, Catherine M., primary, Winer, Eric, primary, and Yardley, Denise A., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figure 1B from A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer

Author

Krop, Ian, primary, Abramson, Vandana, primary, Colleoni, Marco, primary, Traina, Tiffany, primary, Holmes, Frankie, primary, Garcia-Estevez, Laura, primary, Hart, Lowell, primary, Awada, Ahmad, primary, Zamagni, Claudio, primary, Morris, Patrick G., primary, Schwartzberg, Lee, primary, Chan, Stephen, primary, Gucalp, Ayca, primary, Biganzoli, Laura, primary, Steinberg, Joyce, primary, Sica, Lorenzo, primary, Trudeau, Maureen, primary, Markova, Denka, primary, Tarazi, Jamal, primary, Zhu, Zhou, primary, O'Brien, Thomas, primary, Kelly, Catherine M., primary, Winer, Eric, primary, and Yardley, Denise A., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Data from A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer

Author

Krop, Ian, primary, Abramson, Vandana, primary, Colleoni, Marco, primary, Traina, Tiffany, primary, Holmes, Frankie, primary, Garcia-Estevez, Laura, primary, Hart, Lowell, primary, Awada, Ahmad, primary, Zamagni, Claudio, primary, Morris, Patrick G., primary, Schwartzberg, Lee, primary, Chan, Stephen, primary, Gucalp, Ayca, primary, Biganzoli, Laura, primary, Steinberg, Joyce, primary, Sica, Lorenzo, primary, Trudeau, Maureen, primary, Markova, Denka, primary, Tarazi, Jamal, primary, Zhu, Zhou, primary, O'Brien, Thomas, primary, Kelly, Catherine M., primary, Winer, Eric, primary, and Yardley, Denise A., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure 3 from A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer

Author

Krop, Ian, primary, Abramson, Vandana, primary, Colleoni, Marco, primary, Traina, Tiffany, primary, Holmes, Frankie, primary, Garcia-Estevez, Laura, primary, Hart, Lowell, primary, Awada, Ahmad, primary, Zamagni, Claudio, primary, Morris, Patrick G., primary, Schwartzberg, Lee, primary, Chan, Stephen, primary, Gucalp, Ayca, primary, Biganzoli, Laura, primary, Steinberg, Joyce, primary, Sica, Lorenzo, primary, Trudeau, Maureen, primary, Markova, Denka, primary, Tarazi, Jamal, primary, Zhu, Zhou, primary, O'Brien, Thomas, primary, Kelly, Catherine M., primary, Winer, Eric, primary, and Yardley, Denise A., primary

Published
2023
Full Text
View/download PDF

21. Abstract PD6-11: PD6-11 Evaluation of the Sensitivity to Endocrine Therapy Index (SET2,3) in Early Male Breast Cancer: Results from an analysis in the EORTC 10085/TBCRC/BIG/NCTN International Male Breast Cancer Program

Author

Zakon, Danielle B., primary, Poncet, Coralie, additional, Cardoso, Fatima, additional, Anouk, Neven, additional, Valero, Vicente, additional, Aebi, Stefan, additional, Benstead, Kim, additional, Bogler, Oliver, additional, Lago, Lissandra Dal, additional, Fraser, Judith, additional, Caballero, Carmela, additional, Hedenfalk, Ingrid A., additional, Korde, Larissa A., additional, Linderholm, Barbro, additional, Martens, John WM, additional, Middleton, Lavinia P., additional, Murray, Melissa, additional, Kelly, Catherine M., additional, Nilsson, Cecilia, additional, Nowaczyk, Monika, additional, Peeters, Stephanie, additional, Beauvois, Melanie, additional, Porter, Peggy, additional, Schroder, Carolien P., additional, Rubio, Isabel T., additional, Ruddy, Kathryn, additional, van Asperen, Christi, additional, Weyngaert, Danielle Van Den, additional, van Deurzen, Carolien HM, additional, van Leeuwen-Stok, Elise, additional, Vermeij, Joanna M., additional, Bartlett, John MS, additional, Wolff, Antonio C., additional, Giordano, Sharon H., additional, and Symmans, W. Fraser, additional

Published
2023
Full Text
View/download PDF

22. Abstract PD17-06: Immunohistochemical markers and determinants of clinical response in the Penelope-B trial

Author

Knudsen, Erik S., primary, Rachakonda, Sivaramakrishna, additional, Marmé, Frederik, additional, Martín, Miguel, additional, Untch, Michael, additional, Bonnefoi, Hervé R., additional, Schmitt, Wolfgang D., additional, Kim, Sung-Bae, additional, Bear, Harry D., additional, Witkiewicz, Agnieszka, additional, Im, Seock-Ah, additional, DeMichele, Angela, additional, Van’t Veer, Laura, additional, McCarthy, Nicole, additional, Sinn, Bruno V., additional, Gelmon, Karen, additional, García-Sáenz, José Ángel, additional, Kelly, Catherine M., additional, Reimer, Toralf, additional, Turner, Nicholas, additional, Rojo, Federico, additional, Filipits, Martin, additional, Fasching, Peter A., additional, Schem, Christian, additional, Martin, Lesley-Ann, additional, Liu, Yuan, additional, Toi, Masakazu, additional, Rugo, Hope, additional, Gnant, Michael, additional, Makris, Andreas, additional, Furlanetto, Jenny, additional, Weber, Karsten, additional, Denkert, Carsten, additional, and Loibl, Sibylle, additional

Published
2023
Full Text
View/download PDF

23. Abstract HER2-06: HER2-06 Outcome analysis of HER2-zero or HER2-low hormone receptor-positive (HR+) breast cancer patients - characterization of the molecular phenotype in combination with molecular subtyping

Author

Denkert, Carsten, primary, Martín, Miguel, additional, Untch, Michael, additional, Bonnefoi, Hervé R., additional, Knudsen, Erik S., additional, Im, Seock-Ah, additional, DeMichele, Angela, additional, Witkiewicz, Agnieszka, additional, Van ’t Veer, Laura, additional, Kim, Sung-Bae, additional, Bear, Harry D., additional, McCarthy, Nicole, additional, Gelmon, Karen, additional, Marmé, Frederik, additional, García-Sáenz, José Ángel, additional, Turner, Nicholas, additional, Rojo, Federico, additional, Filipits, Martin, additional, Martin, Lesley-Ann, additional, Fasching, Peter A., additional, Schem, Christian, additional, Kelly, Catherine M., additional, Reimer, Toralf, additional, Toi, Masakazu, additional, Rugo, Hope, additional, Gnant, Michael, additional, Makris, Andreas, additional, Liu, Yuan, additional, Weber, Karsten, additional, Rachakonda, Sivaramakrishna, additional, and Loibl, Sibylle, additional

Published
2023
Full Text
View/download PDF

28. Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial

Author

Galactionova, Katya, primary, Loibl, Sibylle, additional, Salari, Paola, additional, Marmé, Frederik, additional, Martin, Miguel, additional, Untch, Michael, additional, Bonnefoi, Hervé R., additional, Kim, Sung-Bae, additional, Bear, Harry D., additional, McCarthy, Nicole, additional, Gelmon, Karen A., additional, García-Sáenz, José A., additional, Kelly, Catherine M., additional, Reimer, Toralf, additional, Toi, Masakazu, additional, Rugo, Hope S., additional, Gnant, Michael, additional, Makris, Andreas, additional, Burchardi, Nicole, additional, and Schwenkglenks, Matthias, additional

Published
2022
Full Text
View/download PDF

33. Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial

Author

Galactionova, Katya, Loibl, Sibylle, Salari, Paola, Marmé, Frederik, Martin, Miguel, Untch, Michael, Bonnefoi, Hervé R, Kim, Sung-Bae, Bear, Harry D, McCarthy, Nicole, Gelmon, Karen A, García-Sáenz, José A, Kelly, Catherine M, Reimer, Toralf, Toi, Masakazu, Rugo, Hope S, Gnant, Michael, Makris, Andreas, Burchardi, Nicole, Schwenkglenks, Matthias; https://orcid.org/0000-0001-7217-1173, Galactionova, Katya, Loibl, Sibylle, Salari, Paola, Marmé, Frederik, Martin, Miguel, Untch, Michael, Bonnefoi, Hervé R, Kim, Sung-Bae, Bear, Harry D, McCarthy, Nicole, Gelmon, Karen A, García-Sáenz, José A, Kelly, Catherine M, Reimer, Toralf, Toi, Masakazu, Rugo, Hope S, Gnant, Michael, Makris, Andreas, Burchardi, Nicole, and Schwenkglenks, Matthias; https://orcid.org/0000-0001-7217-1173

Abstract

BACKGROUND Patients with hormone receptor-positive, HER2-negative breast cancer who have residual invasive disease after neoadjuvant chemotherapy (NACT) are at a high risk of relapse. PENELOPE-B was a double-blind, placebo-controlled, phase III trial that investigated adding palbociclib (PAL) for thirteen 28-day cycles to adjuvant endocrine therapy (ET) in these patients. Clinical results showed no significant improvement in invasive disease-free survival with PAL. METHODS We performed a pre-planned cost-effectiveness analysis of PAL within PENELOPE-B from the perspective of the German statutory health insurance. Health-related quality of life scores, collected in the trial using the EQ-5D-3L instrument, were converted to utilities based on the German valuation algorithm. Resource use was valued using German price weights. Outcomes were discounted at 3% and modeled with mixed-level linear models to adjust for attrition, repeated measurements, and residual baseline imbalances. Subgroup analyses were performed for key prognostic risk factors. Scenario analyses addressed data limitations and evaluated the robustness of the estimated cost-effectiveness of PAL to methodological choices. RESULTS The effects of PAL on quality-adjusted life years (QALYs) were marginal during the active treatment phase, increasing thereafter to 0.088 (95% confidence interval: -0.001; 0.177) QALYs gained over the 4 years of follow-up. The incremental costs were dominated by PAL averaging EUR 33,000 per patient; costs were higher in the PAL arm but not significantly different after the second year. At an incremental cost-effectiveness ratio of EUR 380,000 per QALY gained, PAL was not cost-effective compared to the standard-of-care ET. Analyses restricted to Germany and other subgroups were consistent with the main results. Findings were robust in the scenarios evaluated. CONCLUSIONS One year of PAL added to ET is not cost-effective in women with residual invasive disease after NACT in Germany.

Published
2022

34. Abstract P5-16-08: Phase Ib/II trial evaluating safety and efficacy of copanlisib (PI3K inhibitor) and trastuzumab in pre-treated advanced HER2-positive breast cancer: Results from the PantHER study

Author

Prior, Lisa, primary, Keegan, Niamh M, additional, Furney, Simon J, additional, Walshe, Janice M, additional, Gullo, Giuseppe, additional, Crown, John, additional, Kennedy, M John, additional, Smith, Diarmuid, additional, McCaffrey, John, additional, Kelly, Catherine M, additional, Egan, Keith, additional, Kerr, Jennifer, additional, Given, Mark, additional, Sheehy, Niall, additional, O'Donovan, Peter, additional, Hernando, Andres, additional, Teiserskiene, Ausra, additional, Parker, Imelda, additional, Kay, Elaine, additional, McDermott, Ray, additional, Keane, Maccon M, additional, O'Reilly, Seamus, additional, Grogan, Liam, additional, Breathnach, Oscar, additional, Morris, Patrick G, additional, Toomey, Sinead, additional, and Hennessy, Bryan T, additional

Published
2022
Full Text
View/download PDF

35. Abstract P5-13-36: Germline BRCA1/2 and other predisposition genes in high-risk early-stage HR+/HER2- breast cancer (BC) patients treated with endocrine therapy (ET) with or without palbociclib: A secondary analysis from the PENELOPE-B study

Author

Loibl, Sibylle, primary, Hauke, Jan, additional, Gelmon, Karen, additional, Marmé, Frederik, additional, Ernst, Corinna, additional, Martin, Miguel, additional, Untch, Michael, additional, Bonnefoi, Hervé, additional, Knudsen, Erik, additional, Im, Seock-Ah, additional, DeMichele, Angela, additional, Van’t Veer, Laura, additional, Kim, Sung-Bae, additional, Bear, Harry, additional, McCarthy, Nicole, additional, Turner, Nicholas, additional, Witkiewicz, Agnieszka, additional, Rojo, Federico, additional, Fasching, Peter A, additional, García-Sáenz, José A, additional, Kelly, Catherine M, additional, Reimer, Toralf, additional, Toi, Masakazu, additional, Rugo, Hope S, additional, Denkert, Carsten, additional, Gnant, Michael, additional, Makris, Andreas, additional, Liu, Yuan, additional, Valota, Olga, additional, Felder, Bärbel, additional, Weber, Karsten, additional, Nekljudova, Valentina, additional, and Hahnen, Eric, additional

Published
2022
Full Text
View/download PDF

36. Abstract PD2-04: Molecular plasticity of luminal breast cancer and response to CDK 4/6 inhibition - The biomarker program of the PENELOPE-B trial investigating post-neoadjuvant palbociclib

Author

Denkert, Carsten, primary, Marmé, Frederik, additional, Martin, Miguel, additional, Untch, Michael, additional, Bonnefoi, Hervé, additional, Kim, Sung-Bae, additional, Bear, Harry, additional, Witkiewicz, Agnieszka, additional, Im, Seock-Ah, additional, DeMichele, Angela, additional, Van’t Veer, Laura, additional, McCarthy, Nicole, additional, Stiewe, Thorsten, additional, Gelmon, Karen A., additional, García-Sáenz, José A., additional, Kelly, Catherine M., additional, Reimer, Toralf, additional, Knudsen, Erik, additional, Turner, Nicholas, additional, Rojo, Federico, additional, Fasching, Peter A., additional, Teply-Szymanski, Julia, additional, Liu, Yuan, additional, Toi, Masakazu, additional, Rugo, Hope S., additional, Gnant, Michael, additional, Makris, Andreas, additional, Felder, Bärbel, additional, Weber, Karsten, additional, and Loibl, Sibylle, additional

Published
2022
Full Text
View/download PDF

37. Abstract GS2-07: Updated results from a phase 3 randomized clinical trial in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) ≤ 25 randomized to endocrine therapy (ET) +/- chemotherapy (CT): SWOG S1007 (RxPONDER)

Author

Kalinsky, Kevin M, primary, Barlow, William E, additional, Gralow, Julie R, additional, Meric-Bernstam, Funda, additional, Albain, Kathy S, additional, Hayes, Daniel F, additional, Lin, Nancy U, additional, Perez, Edith A, additional, Goldstein, Lori A, additional, Chia, Stephen KL, additional, Dhesy-Thind, Sukhbinder, additional, Rastogi, Priya, additional, Alba, Emilio, additional, Delaloge, Suzette, additional, Martin, Miguel, additional, Kelly, Catherine M, additional, Ruiz-Borrego, Manuel, additional, Gil-Gil, Miguel, additional, Arce-Salinas, Claudia H, additional, Brain, Etienne GC, additional, Lee, Eun Sook, additional, Pierga, Jean-Yves, additional, Bermejo, Begoña, additional, Ramos-Vasquez, Manuel, additional, Jung, Kyung Hae, additional, Ferrero, Jean-Marc, additional, Schott, Anne, additional, Shak, Steven, additional, Sharma, Priyanka, additional, Lew, Danika, additional, Miao, Jieling, additional, Tripathy, Debasish, additional, Pusztai, Lajos, additional, and Hortobagyi, Gabriel, additional

Published
2022
Full Text
View/download PDF

38. Abstract OT1-12-04: A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP compared with ddAC-THP in patients with high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11)

Author

Harbeck, Nadia, primary, Boileau, Jean-François, additional, Modi, Shanu, additional, Kelly, Catherine M, additional, Ohno, Shinji, additional, Wu, Jiong, additional, Brekenridge, Mark, additional, Herbolsheimer, Pia, additional, Yu, Tinghui, additional, and Pusztai, Lajos, additional

Published
2022
Full Text
View/download PDF

42. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer

Author

Kalinsky, Kevin, primary, Barlow, William E., additional, Gralow, Julie R., additional, Meric-Bernstam, Funda, additional, Albain, Kathy S., additional, Hayes, Daniel F., additional, Lin, Nancy U., additional, Perez, Edith A., additional, Goldstein, Lori J., additional, Chia, Stephen K.L., additional, Dhesy-Thind, Sukhbinder, additional, Rastogi, Priya, additional, Alba, Emilio, additional, Delaloge, Suzette, additional, Martin, Miguel, additional, Kelly, Catherine M., additional, Ruiz-Borrego, Manuel, additional, Gil-Gil, Miguel, additional, Arce-Salinas, Claudia H., additional, Brain, Etienne G.C., additional, Lee, Eun-Sook, additional, Pierga, Jean-Yves, additional, Bermejo, Begoña, additional, Ramos-Vazquez, Manuel, additional, Jung, Kyung-Hae, additional, Ferrero, Jean-Marc, additional, Schott, Anne F., additional, Shak, Steven, additional, Sharma, Priyanka, additional, Lew, Danika L., additional, Miao, Jieling, additional, Tripathy, Debasish, additional, Pusztai, Lajos, additional, and Hortobagyi, Gabriel N., additional

Published
2021
Full Text
View/download PDF

47. Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial

Author

Loibl, Sibylle, primary, Marmé, Frederik, additional, Martin, Miguel, additional, Untch, Michael, additional, Bonnefoi, Hervé, additional, Kim, Sung-Bae, additional, Bear, Harry, additional, McCarthy, Nicole, additional, Melé Olivé, Mireia, additional, Gelmon, Karen, additional, García-Sáenz, José, additional, Kelly, Catherine M., additional, Reimer, Toralf, additional, Toi, Masakazu, additional, Rugo, Hope S., additional, Denkert, Carsten, additional, Gnant, Michael, additional, Makris, Andreas, additional, Koehler, Maria, additional, Huang-Bartelett, Cynthia, additional, Lechuga Frean, Maria Jose, additional, Colleoni, Marco, additional, Werutsky, Gustavo, additional, Seiler, Sabine, additional, Burchardi, Nicole, additional, Nekljudova, Valentina, additional, and von Minckwitz, Gunter, additional

Published
2021
Full Text
View/download PDF

49. Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer “PantHER”

Author

Keegan, Niamh M., primary, Furney, Simon J., additional, Walshe, Janice M., additional, Gullo, Giuseppe, additional, Kennedy, M. John, additional, Smith, Diarmuid, additional, McCaffrey, John, additional, Kelly, Catherine M., additional, Egan, Keith, additional, Kerr, Jennifer, additional, Given, Mark, additional, O’Donovan, Peter, additional, Hernando, Andres, additional, Teiserskiene, Ausra, additional, Parker, Imelda, additional, Kay, Elaine, additional, Farrelly, Angela, additional, Carr, Aoife, additional, Calzaferri, Giulio, additional, McDermott, Ray, additional, Keane, Maccon M., additional, Grogan, Liam, additional, Breathnach, Oscar, additional, Morris, Patrick G., additional, Toomey, Sinead, additional, and Hennessy, Bryan T., additional

Published
2021
Full Text
View/download PDF

50. Abstract GS1-02: Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancerand with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B

Author

Loibl, Sibylle, primary, Marmé, Frederik, additional, Martin, Miguel, additional, Untch, Michael, additional, Bonnefoi, Hervé, additional, Kim, Sung-Bae, additional, Bear, Harry, additional, Carthy, Nicole Mc, additional, Olivé, Mireia Melé, additional, Gelmon, Karen, additional, Sáenz, José García, additional, Kelly, Catherine M, additional, Reimer, Toralf, additional, Toi, Masakazu, additional, Rugo, Hope S, additional, Seiler, Sabine, additional, Nekljudova, Valentina, additional, Denkert, Carsten, additional, Gnant, Michael, additional, Makris, Andreas, additional, Burchardi, Nicole, additional, and von Minckwitz, Gunter, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results